Preethika Mahalingam
Overview
Explore the profile of Preethika Mahalingam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahalingam P, Smith S, Lopez J, Sharma R, Millard T, Thway K, et al.
Rare Tumors
. 2023 Jan;
15:20363613231152333.
PMID: 36698626
Myxopapillary ependymoma (MPE) is a primary tumor of the central nervous system (CNS), characteristically an indolent malignancy involving the spinal conus medullaris, Filum terminale or cauda equina. We present a...
2.
Mahalingam P, Newsom-Davis T
Clin Med (Lond)
. 2023 Jan;
23(1):56-60.
PMID: 36697001
The use of cancer immunotherapies such as immune checkpoint inhibitors (ICIs) has been a paradigm shift in harnessing the immune system to act against cancer cells, and transformed the treatment...
3.
Stansfeld A, Radia U, Goggin C, Mahalingam P, Benson C, Napolitano A, et al.
Expert Opin Pharmacother
. 2022 Sep;
23(14):1641-1650.
PMID: 36102190
Introduction: Anthracycline chemotherapeutic agents are widely used in the treatment of hematological and solid tumors, working principally through DNA intercalation and topoisomerase II inhibition. However, they are also well known...
4.
Goggin C, Stansfeld A, Mahalingam P, Thway K, Smith M, Huang P, et al.
Future Oncol
. 2022 Jul;
18(26):2967-2978.
PMID: 35880452
Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of...
5.
Mahalingam P, Julve M, Huang P, Furness A, Pollack S, Jones R
Curr Opin Oncol
. 2022 Jul;
34(4):362-370.
PMID: 35837706
Purpose Of Review: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date. Recent Findings: Numerous clinical trials are underway...
6.
Kowa J, Millard T, Goldman A, Sharma R, Attygalle A, Mahalingam P, et al.
Br J Haematol
. 2021 Jun;
195(1):e116-e119.
PMID: 34109610
No abstract available.
7.
Turton P, El-Sharkawi D, Lyburn I, Sharma B, Mahalingam P, Turner S, et al.
J Plast Reconstr Aesthet Surg
. 2021 Jan;
74(1):13-29.
PMID: 33483089
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T cell Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast...
8.
Turton P, El-Sharkawi D, Lyburn I, Sharma B, Mahalingam P, Turner S, et al.
Eur J Surg Oncol
. 2020 Dec;
47(2):199-210.
PMID: 33358076
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T cell Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast...
9.
Turton P, El-Sharkawi D, Lyburn I, Sharma B, Mahalingam P, Turner S, et al.
Br J Haematol
. 2020 Nov;
192(3):444-458.
PMID: 33222158
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants...